Evidence map›Paper›PMID 39141742›Full record

ArticleScience advances2024

In situ implantable DNA hydrogel for diagnosis and therapy of postoperative rehemorrhage following intracerebral hemorrhage surgery.

Wenyan Yu, Enpeng Gong, Changlin Wang, Chengyuan Che, Yuzhen Zhao, Xinyun Wu, Yi Yang, Haiyu Shi, Mengjuan Chen, Mingge Li and 9 more

Abstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Wenyan YuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Enpeng GongSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Changlin WangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Chengyuan CheSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Yuzhen ZhaoSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Xinyun WuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Yi YangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Haiyu ShiSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Mengjuan ChenSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Mingge LiSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Li XieSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Yue GuoSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Mingming GuoSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Liya MuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Zhenya WangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0001-6880-1849
Zhenzhong ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0003-1558-6019
Kaixiang ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0002-6812-6342
Junjie LiuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0002-9404-050X
Jinjin ShiSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0003-1531-7265

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postoperative rehemorrhage following intracerebral hemorrhage surgery is intricately associated with a high mortality rate, yet there is now no effective clinical treatment. In this study, we developed a hemoglobin (Hb)-responsive in situ implantable DNA hydrogel comprising Hb aptamers cross-linked with two complementary chains and encapsulating deferoxamine mesylate (DFO). Functionally, the hydrogel generates signals upon postoperative rehemorrhage by capturing Hb, demonstrating a distinctive "self-diagnosis" capability. In addition, the ongoing capture of Hb mediates the gradual disintegration of the hydrogel, enabling the on-demand release of DFO without compromising physiological iron-dependent functions. This process achieves self-treatment by inhibiting the ferroptosis of neurocytes. In a collagenase and autologous blood injection model-induced mimic postoperative rehemorrhage model, the hydrogel exhibited a 5.58-fold increase in iron absorption efficiency, reducing hematoma size significantly (from 8.674 to 4.768 cubic millimeters). This innovative Hb-responsive DNA hydrogel not only offers a therapeutic intervention for postoperative rehemorrhage but also provides self-diagnosis feedback, holding notable promise for enhancing clinical outcomes.

Indexed as

Cerebral HemorrhageHemoglobinsHydrogelsAnimalsAptamers, NucleotideDeferoxamineDisease Models, AnimalDNAFerroptosisHumansIronMalePostoperative HemorrhageRatsAptamers, NucleotideDeferoxamineDNAHemoglobinsHydrogelsIron

Identifiers

PMID39141742
PMCPMC11323940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.